ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation

American Journal of Health-System Pharmacy

Volumn 64, Issue 21, 2007, Pages 2281-2291

  Nutescu, Edith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

American Society of Health System Pharmacists; Anticoagulants; Aspirin; Atrial fibrillation; Cerebrovascular accident; Pharmacists; Platelet aggregation inhibitors; Protocols; Toxicity; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FLUINDIONE; PLACEBO; VITAMIN K GROUP; WARFARIN;

AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HEALTH CARE ORGANIZATION; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE;

EID: 36049028379     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070301     Document Type: Review

References (86)

1. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3, suppl):429S-56S.
2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001; 285:2370-5.
3. Feinberg WM, Blackshear IL, Laupacis A et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995; 155:469-73.
4. Furberg CD, Psaty BM, Manolio TA et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994; 74:236-41.
5. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003; 108:711-6.
6. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983-8.
7. Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart. 2006; 92:155-61.
8. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98:946-52.
9. Marini C, De Santis F, Sacco S et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005; 36:1115-9.
10. Paciaroni M, Agnelli G, Caso V et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost. 2005; 3:1218-23.
11. Falk RH. Atrial fibrillation. N Engl J Med. 2001; 344:1067-78. [Erratum, N Engl J Med. 2001; 344:1876.]
12. Go AS, Hylek EM, Borowsky LH et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med. 1999; 131:927-34.
13. Villa A, Bacchetta A, Omboni E. Underuse of antithrombotic therapy in stroke patients with chronic atrial fibrillation. Stroke. 2000;31:2266-7.
14. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003; 41:56-61.
15. American Society of Health-System Pharmacists. ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. Am J Health-Syst Pharm. 1998; 55:376-81.
16. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation. 2006; 114:700-52. [Erratum, Circulation. 2007; 116:e137.]
17. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med. 1992; 116:6-12.
18. Laupacis A, Sackett DL, Robert RS. An assessment of clinically useful measurements of the consequences of treatment. N Engl J Med. 1988; 318:1728-33.
19. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154:1449-57.
20. Stroke Prevention in Atrial Fibrillation. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation study. J Stroke Cerebrovasc Dis. 1995; 5:147-57.
21. Hart RG, Pearce LA, McBride R et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke. 1999; 30:1223-9.
22. Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003; 290:1049-56.
23. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification-schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2864-70.
24. Go AS. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care. 2004; 10:S58-65.
25. Gage BF, van Walraven C, Pearce L et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004; 110:2287-92.
26. Pearce LA, Hart RG, Halperin IL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 2000; 109:45-51.
27. Petersen P, Boysen G, Godtfredsen J et al. Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation (AFASAK). Lancet. 1989; 1:175-9.
28. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-11.
29. The Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84:527-39.
30. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327:1406-12. [Erratum, N Engl J Med. 1993; 328:148.]
31. Connolly SJ, Laupacis A, Gent M et al., for the CAFA Study Co-investigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991; 18:349-55.
32. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993; 342:1255-62.
33. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995; 333:5-10.
34. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the prevention of stroke. J Neurol Sci. 1996; 143:1-13.
35. Diener HC, Lowenthal A. Reply. (Anti-platelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibillation.) J Neuorol Sci. 1997; 153:112. Letter.
36. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. Am Heart J. 1999; 138:137-43.
37. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994; 343:687-91.
38. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996; 348:633-8.
39. Gullov AL, Koefoed BG, Petersen P et al. Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998; 158:1513-21.
40. Hellemons BS, Langenberg M, Lodder J et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomized controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999; 318:958-64.
41. Hart RG, Talbert RL, Kadri K et al. Warfarin for stroke prevention: a clinical review. Neurologist. 1996; 2:319-41.
42. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med. 1997; 157:1237-40.
43. Hart RG, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131:492-501.
44. Van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002; 288:2441-8.
45. Hart RG, Pearce LA, Miller VT et al. Cardioembolic versus noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000; 10:39-43.
46. Lin HI, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke. 1996; 27:1760-4.
47. Hylek EM, Go AS, Chang Y et al. Impact of intensity of oral anticoagulation on stroke severity and stroke mortality in patients with non-valvular atrial fibrillation. N Engl J Med. 2003; 349:1019-26.
48. Lechat P, Lardoux H, Mallet A et al. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS). Cerebrovasc Dis. 2001; 12:245-52.
49. Hylek EM, Skates SI, Sheehan MA et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335:540-6.
50. Brass LM, Krumholz HM, Scinto JM et al. Warfarin use among patients with atrial fibrillation. Stroke. 1997; 28:2382-9.
51. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471-7.
52. Gottleib LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994; 154:1945-53.
53. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996; 156:409-16.
54. Fihn SD, Callahan CM, Martin DC et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996; 124:970-9.
55. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception cohort, prospective collaborative study. Lancet. 1996; 348:423-8.
56. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994; 120:897-902.
57. Goerter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology. 1999; 53:1319-27.
58. Cannegiter SC, Rosendaal FR, Wintzen AR et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-7.
59. Ansell J, Hirsh J, Poller L et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126:204S-233S.
60. Kagansky N, Knobler H, Rimon E et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med. 2004; 164:2044-50.
61. Go AS, Hylek EH, Chang Y et al. Anticoagulation for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003; 290:2685-92.
62. Palareti G, Manotti C, D'Angelo A et al. Thrombotic events during anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study. Thromb Haemost. 1997; 78:1438-43.
63. Snow W, Weiss KB, LeFevre M et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2003; 139:1009-17.
64. Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Clin Geriatr Med. 2006; 22:33-56.
65. Idraparinux sodium: SANORG 34006, SR 34006. Drugs R D. 2004; 5:164-5.
66. Buller H. Once-weekly subcutaneous idraparinux (anti-XA) versus oral vitamin K antagonist therapy for the prevention of thromboembolic events in patients with atrial fibrillation (O-W-054). Paper presented at 21st Congress of the International Society on Thrombosis and Haemostasis. Geneva; 2007 Jul 11.
67. The Active Steering Committee. Rationale and design of ACTIVE: the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. Am Heart J. 2006;151:1187-93.
68. ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367:1903-12.
69. American Heart Association. Heart disease and stroke statistics - 2006 update. www.americanheart.org/downloadable/heart/113535864858055- 1026_HS_Stats06book.pdf (accessed 2006 Mar 1).
70. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004; 10:S451-61.
71. Caro JJ, Huybrechts KF, Duchesne I, for the Stroke Economic Analysis Group. Management patterns and costs of acute ischemic stroke: an international study. Stroke. 2000; 31:582-90.
72. Bungard TJ, Ackman ML, Ho G et al. Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. Pharmacotherapy. 2000; 20:1060-5.
73. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347:1825-33.
74. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med. 1998; 158:1669-77.
75. Gage BF, Cardinalli AB, Albers GW et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995; 274:1839-45.
76. Kan BD, Katz DA. Cost-effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation. JAMA. 1996; 275:909. Letter.
77. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in non-rheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke. 1998; 29:1827-32.
78. Szucs TD, Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost. 2006; 4:1180-5.
79. Nutescu EA, Helgason CM. Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis. Curr Treat Options Cardiovasc Med. 2005; 7:241-50.
80. American Society of Health-System Pharmacists. ASHP therapeutic position statement on the use of the International Normalized Ratio system to monitor oral anticoagulant therapy. Am J Health-Syst Pharm. 1995; 52:529-31.
81. Radley AS, Hall J, Farrow M et al. Evaluation of anticoagulant control in a pharmacist operated anticoagulant clinic. J Clin Pathol. 1995; 48:545-7.
82. Lee YP, Schommer IC. Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions. Am J Health-Syst Pharm. 1996; 53:1580-3.
83. Witt DM, Sadler MA, Shanahan RL et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005; 127:1515-22.
84. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J. 1996; 132:1095-100.
85. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998; 158:1641-7.
86. Wilt VM, Gums IG, Ahmed OI et al. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy. 1995; 15:732-9.